Antibodies against malondialdehyde among 60-year-olds: prediction of cardiovascular disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 09 2023
11 09 2023
Historique:
received:
21
03
2023
accepted:
07
09
2023
medline:
13
9
2023
pubmed:
12
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Malondialdehyde (MDA) is generated in oxidized LDL. It forms covalent protein adducts, and is recognized by antibodies (anti-MDA). We previously studied IgM anti-MDA, and here we focus on IgG, IgG1 and IgG2 anti-MDA in predicting cardiovascular disease (CVD). We determined, by ELISA, anti-MDA in a 7-year follow-up of 60-year-old men and women from Stockholm County (2039 men, 2193 women). We identified 210 incident CVD cases (defined as new events of myocardial infarction (MI), and hospitalization for angina pectoris) and ischemic stroke, and 620 age- and sex-matched controls. IgG anti-MDA was not associated with CVD. Median values only differed significantly for IgG1 anti-MDA among men, with lower levels among cases than controls (p = 0.039). High IgG1 anti-MDA (above 75th percentile) was inversely associated with CVD risk after adjustment for smoking, body mass index, type 2 diabetes, hyperlipidemia, and hypertension, (OR and 95% CI: 0.59; 0.40-0.89). After stratification by sex, this association emerged in men (OR and 95% CI: 0.46; 0.27-0.77), but not in women. IgG2 anti-MDA were associated with protection in the whole group and among men though weaker than IgG1 anti-MDA. IgG2 anti-MDA above the 75th percentile was associated with an increased risk of MI/angina in women (OR and 95% CI: 2.57; (1.08-6.16)). IgG1 and less so IgG2 anti-MDA are protection markers for CVD and MI/angina in the whole group and among men. However, IgG2 anti-MDA was a risk marker for MI/angina among women. These findings could have implications for both prediction and therapy.
Identifiants
pubmed: 37697019
doi: 10.1038/s41598-023-42264-1
pii: 10.1038/s41598-023-42264-1
pmc: PMC10495339
doi:
Substances chimiques
Malondialdehyde
4Y8F71G49Q
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15011Informations de copyright
© 2023. Springer Nature Limited.
Références
Frostegard, J. et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33–43 (1999).
pubmed: 10428293
Frostegard, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 11, 117 (2013).
pubmed: 23635324
pmcid: 3658954
Wu, R., de Faire, U., Lemne, C., Witztum, J. L. & Frostegard, J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33, 53–59 (1999).
pubmed: 9931081
Frostegard, J. Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation. Expert Rev. Clin. Immunol. 18, 525–532 (2022).
pubmed: 35471137
Fogelman, A. M. et al. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA 77, 2214–2218 (1980).
pubmed: 6769124
pmcid: 348683
Duryee, M. J. et al. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic. Biol. Med. 49, 1480–1486 (2010).
pubmed: 20696236
pmcid: 2952714
Thiagarajan, D. et al. Human IgM antibodies to malondialdehyde conjugated with albumin are negatively associated with cardiovascular disease among 60-year-olds. J. Am. Heart Assoc. 5, e004415 (2016).
pubmed: 27998914
pmcid: 5210446
Halldin, M., Rosell, M., de Faire, U. & Hellenius, M. L. The metabolic syndrome: Prevalence and association to leisure-time and work-related physical activity in 60-year-old men and women. Nutr. Metab. Cardiovasc. Dis. 17, 349–357 (2007).
pubmed: 17562572
Samal, S. K., Fröbert, O., Kindberg, J., Stenvinkel, P. & Frostegård, J. Potential natural immunization against atherosclerosis in hibernating bears. Sci. Rep. 11, 12120 (2021).
pubmed: 34108551
pmcid: 8190116
Samal, S. K., Qureshi, A. R., Rahman, M., Stenvinkel, P. & Frostegård, J. Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: Association with mortality. Clin. Exp. Immunol. 201, 94–104 (2020).
pubmed: 32297318
pmcid: 7290086
Samal, S. K., Qureshi, A. R., Rahman, M., Stenvinkel, P. & Frostegård, J. Antibodies against malondialdehyde in haemodialysis patients and its association with clinical outcomes: Differences between subclasses and isotypes. J. Clin. Med. 9, 753 (2020).
pubmed: 32168733
pmcid: 7141181
Sun, J. et al. Effects of atorvastatin on T-cell activation and apoptosis in systemic lupus erythematosus and novel simulated interactions with C-reactive protein and interleukin 6. ACR Open Rheumatol. 3, 642–653 (2021).
pubmed: 34302321
pmcid: 8449041
de Faire, U. et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: Effects on uptake of oxidized LDL in macrophages as a potential mechanism. J. Autoimmun. 34, 73–79 (2010).
pubmed: 19726160
Samal, S. K. et al. Antibodies against phosphorylcholine among 60-year-olds: Clinical role and simulated interactions. Front. Cardiovasc. Med. 9, 809007 (2022).
pubmed: 35479288
pmcid: 9035555
Freigang, S., Horkko, S., Miller, E., Witztum, J. L. & Palinski, W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb. Vasc. Biol. 18, 1972–1982 (1998).
pubmed: 9848892
Marziale, A. et al. Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. J. Autoimmun. 115, 102524 (2020).
pubmed: 32693965
Palinski, W., Miller, E. & Witztum, J. L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92, 821–825 (1995).
pubmed: 7846059
pmcid: 42712
Salonen, J. T. et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339, 883–887 (1992).
pubmed: 1348295
Bergmark, C., Wu, R., de Faire, U., Lefvert, A. K. & Swedenborg, J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb. Vasc. Biol. 15, 441–445 (1995).
pubmed: 7749854
Puurunen, M. et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154, 2605–2609 (1994).
pubmed: 7979858
Wu, R. et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb. Vasc. Biol. 17, 3159–3163 (1997).
pubmed: 9409306
Lehtimaki, T. et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb. Vasc. Biol. 19, 23–27 (1999).
pubmed: 9888862
Palinski, W., Tangirala, R. K., Miller, E., Young, S. G. & Witztum, J. L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb. Vasc. Biol. 15, 1569–1576 (1995).
pubmed: 7583529
van de Vijver, L. P. et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122, 245–253 (1996).
pubmed: 8769687
Virella, G., Virella, I., Leman, R. B., Pryor, M. B. & Lopes-Virella, M. F. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23, 95–101 (1993).
pubmed: 8518420
Uusitupa, M. I. et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb. Vasc. Biol. 16, 1236–1242 (1996).
pubmed: 8857919
Karvonen, J., Paivansalo, M., Kesaniemi, Y. A. & Horkko, S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108, 2107–2112 (2003).
pubmed: 14530200
Su, J. et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188, 160–166 (2006).
pubmed: 16307748
Rontu, R. et al. Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis. Clin. Chem. Lab. Med. 43, 357–360 (2005).
pubmed: 15899649
Maiolino, G. et al. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. Int. J. Cardiol. 168, 484–489 (2013).
pubmed: 23102599
Sjogren, P. et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur. Heart J. 29, 2218–2226 (2008).
pubmed: 18664466
Fredrikson, G. N. et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb. Vasc. Biol. 23, 872–878 (2003).
pubmed: 12649091
Vaarala, O. et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341, 923–925 (1993).
pubmed: 8096266
Hughes, G. R., Harris, N. N. & Gharavi, A. E. The anticardiolipin syndrome. J. Rheumatol. 13, 486–489 (1986).
pubmed: 3735270
Frostegard, A. G. et al. Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development. PLoS ONE 9, e111764 (2014).
pubmed: 25473948
pmcid: 4256296
Hamsten, A., Norberg, R., Bjorkholm, M., de Faire, U. & Holm, G. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1, 113–116 (1986).
pubmed: 2867345
Ludwig, R. J. et al. Mechanisms of autoantibody-induced pathology. Front. Immunol. 8, 603 (2017).
pubmed: 28620373
pmcid: 5449453
Lopes-Virella, M. F. et al. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 224, 526–531 (2012).
pubmed: 22963984
pmcid: 4240617
Matsuura, E., Kobayashi, K., Matsunami, Y. & Lopez, L. R. The immunology of atherothrombosis in the antiphospholipid syndrome: Antigen presentation and lipid intracellular accumulation. Autoimmun. Rev. 8, 500–505 (2009).
pubmed: 19171205
Rahman, M. et al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Clin. Immunol. 166–167, 27–37 (2016).
pubmed: 27102765
Taleb, A. et al. High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction. J. Lipid Res. 64, 100391 (2023).
pubmed: 37211249
pmcid: 10275726